Therapeutic Response
CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cyclophosphamide, Doxorubicin, and Prednisone in patients with Mycosis Fungoides.
Statements
| Source and description |
|---|
CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cyclophosphamide, Doxorubicin, and Prednisone in patients with Mycosis Fungoides.
| Source and description |
|---|